Clinical Trials Logo

SARS Pneumonia clinical trials

View clinical trials related to SARS Pneumonia.

Filter by:

NCT ID: NCT04357340 Completed - Covid-19 Clinical Trials

The Effects of Pulmonary Physiotherapy Treatments on Patients With COVID-19

Start date: April 2, 2020
Phase: N/A
Study type: Interventional

The aim of this study is to evaluate the efficacy of pulmonary physiotherapy on respiratory functions in hospitalized patients with Novel Coronavirus 2019 pneumonia. Patients will be randomized into 1) intervention group: receiving pulmonary physiotherapy technique to improve pulmonary function and walking training or 2) control group: Usual medical care. Patients in both groups will receive therapeutic incentive spirometer. Various outcome measurements of pulmonary functions will be evaluated before and after of interventions. Mortality rate, hospitalization duration and re-admission will be followed until one month after end of intervention. Also, patient's quality of life will be measured after one month.

NCT ID: NCT04315480 Active, not recruiting - SARS Pneumonia Clinical Trials

Tocilizumab for SARS-CoV2 (COVID-19) Severe Pneumonitis

Start date: March 12, 2020
Phase: Phase 2
Study type: Interventional

In a Phase 2 Simon's Optimal Two-Stages Design intravenous tocilizumab will be administered as single 8mg/Kg dose in patients affected by severe multifocal interstitial pneumonia correlated to SARS-CoV2 infection. Aim of the study is to test the hypothesis that an anti-IL6 treatment can be effective in calming the virus-induced cytokine storm, blocking deterioration of lung function or even promoting a rapid improvement of clinical conditions, preventing naso-tracheal intubation and/or death.